CVR 45929345Private limited company (ApS)Fremstilling af farmaceutiske præparater (212000)SøborgFounded 1 Oct 2025
CVR holds no employment figures for this company.
Compiled by Dandex from the Central Business Register (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Dandex is Danish company data. Connect it once and ask about Novithera ApS, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Set Up DandexGross profit
-48K
DKK, annual report 2026
Result
-54.1K
DKK, annual report 2026
Equity
-34.1K
DKK, annual report 2026
Nordicus Partners Corporation50% to under 66.7% of capital and votes, since 1 Oct 2025
Alteral Therapeutics ApSCVR 43730967, 33.3% to under 50% of capital and votes, since 1 Oct 2025
Christian Torben Hill-Madsensince 1 Oct 2025
Allan Traugott Wehnertsince 1 Oct 2025
Equity was negative at 31 Mar 2026: -34.1K DKK. Dandex estimate, computed 4 Nov 2026.
CVR 4373096733.3% to under 50% of capital and votessince 1 Oct 2025
50% to under 66.7% of capital and votessince 1 Oct 2025
Holders of 5% or more, from the owner register. CVR records shares in bands, not exact figures.
CVR records founders at incorporation. It does not record whether they are alive or still involved.
1 Oct 2025 to 4 Nov 2026.
| Metric | 2026 |
|---|---|
| Gross profit | -48 |
| Result for the year | -54 |
| Equity | -34 |
| Total assets | 664 |
| Employees (average) | 0 |
| Credit metrics (Dandex calculations) | |
| Net interest-bearing debt (NIBD, nettorentebærende gæld) | -30note 1 |
| Capex (investeringer i anlægsaktiver) | 563note 2 |
| NIBD incl. group and owner balances (NIBD inkl. koncern- og ejermellemværender) | 168note 1 |
DKK thousands. Annual reports via XBRL. Employees are the annual report's average and may cover a group. 2026 covers 6 months (1 Oct 2025 to 31 Mar 2026).
Credit metrics are Dandex calculations from the filed figures, not filed values; estimates are in grey with a note. Ratios are percentages and gearing a multiple. Definitions. Revenue-based rows are empty: the company reports gross profit only (bruttofortjeneste), which class B filers may. No cash flow statement filed (class A and B are exempt).
Annual report 2026
1 Oct 2025 to 31 Mar 2026, published 1 Oct 2026
Novithera ApS har en Z'-Score på -1.32 (nødlidende zone). Virksomheden viser tegn på økonomisk pres baseret på regnskabsdata.
Signal, a Dandex estimate. Lapses 6 Apr 2027.
Each registered value from the day it took effect, newest first.
From CVR, read 4 Nov 2026. Text such as the signing rule and purpose is shown as registered.
3 registrations, newest first. As published by Erhvervsstyrelsen, in Danish, with people's street addresses cut to postcode and city.
Ny adresse: Vandtårnsvej 62A, 1. b, 2860 Søborg
Ny adresse: Vandtårnsvej 62A, 1. e, 2860 Søborg
Ny kommune: Gladsaxe
Stiftelsesdato: 01.10.2025.
Virkningsdato: 01.10.2025.
Seneste vedtægtsdato: 01.10.2025.
Kapital:
kr. 20.000,00.
Kapitalklasser: Nej
Indbetalingsmåde: Indbetalt kontant kr. 20.000,00 til kurs 100,00, fuldt indbetalt.
Stifter:
Nordicus Partners Corporation, den 01.10.2025.
Direktion:
Christian Torben Hill-Madsen, den 01.10.2025, Allan Traugott Wehnert, den 01.10.2025.
Selskabet tegnes af den samlede direktion.
Revision:
CVR-NR. 33256876 CROWE STATSAUTORISERET REVISIONSINTERESSENTSKAB, Rygårds Allé 104, 2900 Hellerup, den 01.10.2025.
Første regnskabsår:
01.10.2025 - 31.03.2026.
Regnskabsår:
01.04 - 31.03.
Formål:
Selskabets formål er at udvikle lægemidler samt dermed beslægtet virksomhed.
1 registered in CVR.
P-number 1031727169Vandtårnsvej 62, 2860 Søborg
